PIK3C2A and rhabdomyolysis: Two patients developed grade 2 fatigue (18%) at 8 and 12 months, respectively, after the onset of immunotherapy, without CPK elevation (indicating absence of rhabdomyolysis), and were treated with a similar methylprednisolone schedule.